Aceclofenac is relevant in contexts involving heightened systemic burden and symptoms related to inflammatory or irritative states. It is utilized in the management of symptoms related to physical discomfort and inflammatory or irritative processes, commonly used for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

---

Support in Managing Acute Discomfort

Aceclofenac is considered relevant in general clinical scenarios where symptoms intensify suddenly, and is commonly used when short-term symptomatic assistance is needed. It provides support that contributes to easing the overall symptom load, especially during phases of increased distress or discomfort.

---

Addressing Localized Symptom Patterns and Functional Strain

This medication is applied in addressing symptoms related to physical discomfort and managing symptom clusters that may create noticeable interference with daily functioning. It offers symptomatic relief and contributes to improved day-to-day comfort during periods of heightened symptoms, and assists with maintaining functional stability during difficult, localized episodes.

"It is commonly used to help with symptom clusters that may become intense or disruptive and interfere with daily comfort."

---

Support for Conditions with Fluctuating Symptom Burdens

Proflam is commonly used across condition categories characterized by episodic or fluctuating symptom manifestations. It is applied across domains where additional symptomatic support is needed, helping to support physical comfort during symptomatic phases when disruptive symptoms become more noticeable.

Quick Fact: Support for Symptoms Related to Physical Discomfort

Regulatory References

1. Medicines and Healthcare products Regulatory Agency (MHRA) guidance

Eligibility Map: Who Can and Cannot Use Proflam (Aceclofenac) — Official Regulatory Information

Official regulatory documents classify patient eligibility for Aceclofenac, a Nonsteroidal Anti-inflammatory Drug (NSAID), based on age, physiological status, and the presence of severe medical conditions.

---

Eligibility Scope

• Populations for whom use is allowed: Generally adults (18 years and older) who do not possess any absolute contraindications are permitted to use the medicine under standard labeled conditions.
• Populations for whom use is contraindicated: Use is strictly prohibited for patients with:
  • Severe organ failure (hepatic or renal failure).
  • Established severe cardiovascular diseases (e.g., congestive heart failure NYHA II–IV, ischaemic heart disease, or cerebrovascular disease).
  • Active or recurrent peptic ulcer/haemorrhage or active bleeding disorders.
  • Known hypersensitivity to aceclofenac, aspirin, or other NSAIDs.
  • Women in the last trimester of pregnancy.

---

Age and Condition-Specific Eligibility Rules

Classification	Eligibility Rule	Condition for Use
Age Restriction	Not recommended for children and adolescents (under 18) due to insufficient clinical data.	Elderly patients require caution and close monitoring.
Organ Impairment	Contraindicated in severe hepatic or renal failure.	Caution is required for mild-to-moderate impairment.
Pregnancy/Lactation	Contraindicated in the last trimester; not recommended in the first six months or during breastfeeding.	Not applicable

These official eligibility constraints define the mandatory exclusion criteria, reserving use for individuals whose health profile aligns with the accepted safety parameters of the NSAID class.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Aceclofenac as reported in government regulatory documents.

Interaction-Related Restrictions

• Contraindicated Combinations: Co-administration with other NSAIDs, including analgesic doses of aspirin and COX-2 selective inhibitors, must be avoided due to a significantly increased risk of adverse effects, particularly gastrointestinal bleeding.
• Timing Requirement: Aceclofenac should not be used for 8–12 days following the administration of Mifepristone.

Pharmacodynamic and Exposure Interactions

Aceclofenac has officially documented interactions that primarily fall into two domains: altering drug exposure and increasing risk.

• Increased Exposure: Co-administration with Lithium or Methotrexate may formally increase the plasma levels of these substances, necessitating caution due to reduced clearance.
• Efficacy Interference: Aceclofenac may officially reduce the anti-hypertensive effect of ACE inhibitors or Angiotensin II Receptor Antagonists and diminish the effect of diuretics, increasing the risk of nephrotoxicity.
• Additive Risk: Combining Aceclofenac with anticoagulants (e.g., Warfarin), corticosteroids, or SSRIs may enhance the risk of bleeding or gastrointestinal ulceration. Risk of adverse reactions is formally noted to be increased in the elderly population.

Primary Mechanism: Cyclooxygenase (COX) Enzyme Inhibition

Aceclofenac's primary mechanistic activity involves the inhibition of cyclooxygenase (COX) enzymes (specifically COX-1 and COX-2) within the eicosanoid synthesis pathway. This molecular action immediately modifies the early steps of the arachidonic acid metabolic cascade, an enzyme pathway involved in the biosynthesis of prostanoids. Aceclofenac is considered a precursor that is metabolized to its active moiety, which then acts to block the active sites of these COX enzymes.

---

Reduction in Eicosanoid Mediator Synthesis

Inhibition of COX activity results in a reduction in the synthesis of prostaglandins and other eicosanoid mediators (PGE2). Limiting the formation of these key signaling molecules modifies pathway dynamics that influence local physiological responses. This interference targets the molecular machinery responsible for the cellular release of these specific mediators in response to local stimuli.

---

Modulation of Peripheral Signaling Activity

The change in mediator concentration modifies peripheral signal transduction, influencing downstream pathway activity. Inhibition of eicosanoid activity at the tissue level modifies the processes that govern local microvascular permeability and the activity of sensory neurons (nociceptors), thereby influencing systemic physiological response patterns.

How to Use Proflam (Aceclofenac): Administration Guidelines

Aceclofenac is primarily administered via the oral route, typically formulated as a 100 mg film-coated tablet or as a powder for oral suspension. The fundamental principle governing its use is to administer the lowest effective dose for the shortest duration required to manage symptomatic states.

---

Standard Dosage and Frequency

Feature	Usage Principle
Standard Daily Dose	200 mg
Frequency Pattern	Twice daily (BID) using the 100 mg tablet.
Administration Timing	Should be taken with or immediately after food to optimize use.
Tablet Handling	Tablets must be swallowed whole with water; crushing or chewing is not permitted.

---

Procedural and Population Constraints

Specific procedural boundaries apply to the use of this medication. Patients with mild to moderate hepatic impairment require their initial daily dose to be reduced to 100 mg (once daily). For the pediatric population, use is not recommended due to a lack of sufficient clinical data. If a dose is missed, the user should skip the forgotten dose and resume the schedule at the next regular time; a double dose should not be taken.

Treatment duration is subject to periodic professional re-evaluation to confirm the ongoing need for therapy, ensuring adherence to the shortest possible use period.

Research evidence / Overview of studies for Proflam (Aceclofenac)

This overview summarizes the type of research that has been conducted on Aceclofenac (Proflam) and what is known—and still uncertain—about its use, based only on official and peer-reviewed scientific sources.

---

Research Evidence for Osteoarthritis

Research primarily used randomized controlled trials (RCTs), including observational designs, to examine the use of Aceclofenac in adult outpatients dealing with conditions marked by functional limitations, such as chronic osteoarthritis. These studies was studied for outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. The trials usually include comparison groups such as a placebo or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Studies describe patterns observed in the short-term measurement of outcomes related to physical discomfort in the observed populations. When these individual studies are combined in meta-analyses, the evidence quality varies across studies, with a more consistent pattern of findings reported for symptomatic endpoints than for functional outcomes.

---

Research Evidence for Rheumatoid Arthritis and Ankylosing Spondylitis

Aceclofenac was studied for conditions characterized by fluctuating or episodic manifestations, such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Research for these conditions mostly utilizes comparative randomized controlled trials, where Aceclofenac was studied in adult populations with active disease symptoms. These studies examined specific, objective outcomes linked to inflammatory or irritative states, such as the count of swollen and tender joints, and the duration of morning stiffness.

Trials reported changes measured during the study period for these objective endpoints. Findings indicate patterns related to outcomes linked to inflammatory or irritative states over the observed time intervals. The evidence contributes to the broader evidence landscape over short-term courses of treatment.

---

Long-Term Studies and Follow-Up Data

The main clinical research supporting the use of Aceclofenac for chronic conditions like arthritis primarily involves follow-up durations that were limited to several weeks or a few months (typically up to 6 months). These studies contribute to the broader evidence landscape by showing what has been observed in the short term. Long-term outcomes are not fully established regarding the sustained control of these chronic conditions.

---

What is Still Uncertain About the Research

A primary limitation is that long-term outcomes are not fully established, particularly concerning the outcomes observed over several years of use for chronic conditions. The evidence quality varies across studies due to factors like high heterogeneity (differences in study design) found when trials are combined in meta-analyses. Furthermore, comparative evidence is lacking for certain patient populations, and data for certain groups remain insufficient. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders

Common questions about Proflam (Aceclofenac) (FAQ)

Q: How long does the effect of one dose of Proflam (Aceclofenac) usually last?

Regulatory information indicates that the approximate half-life of Aceclofenac in the body is around four hours. This characteristic is considered when establishing the recommended twice-daily dosing schedule. The actual duration of pain relief observed can vary between individuals.

Q: Is Proflam (Aceclofenac) a long-term treatment or just for short-term use?

Official regulatory guidelines define that the medicine should be used for the lowest effective dose for the shortest duration necessary to control symptoms. Treatment duration should be subject to periodic professional re-evaluation.

Q: Is it normal to feel a bit nauseous after taking Proflam (Aceclofenac)?

Yes, regulatory documents list nausea as a common adverse reaction associated with Aceclofenac use, affecting between 1 and 10 out of 100 users. Regulatory materials advise seeking guidance if severe or persistent adverse effects occur.

Q: Is Proflam (Aceclofenac) known to cause stomach upset more often than other similar drugs?

Official safety documents list stomach pain, dyspepsia (indigestion), and nausea as common side effects. As an NSAID, the medication carries a recognized risk of serious gastrointestinal events, which is formally noted to increase with higher doses or longer duration of use.

Q: Is Proflam (Aceclofenac) safe to use during pregnancy, based on regulatory information?

Regulatory information states that this medicine is contraindicated (must not be used) during the third trimester of pregnancy. Use during the first six months is generally not recommended, and consultation with a professional is typically recommended prior to use.

Q: Can Proflam (Aceclofenac) be used while breastfeeding, according to regulatory data?

Official regulatory data generally recommend against the use of Aceclofenac while breastfeeding. This is due to insufficient data confirming if the medicine is excreted into breast milk or its potential effects.

Q: Does Proflam (Aceclofenac) affect the kidneys?

As an NSAID, use in patients with severe kidney problems is strictly contraindicated. Regulatory information notes the potential for NSAIDs to affect kidney function and can sometimes cause fluid retention, which can be relevant for kidney health.

Q: Why is Proflam (Aceclofenac) sometimes prescribed for different types of pain?

Aceclofenac is officially indicated for the symptomatic treatment of pain and inflammation. Its core indications are related to chronic joint diseases like osteoarthritis and rheumatoid arthritis, which are characterized by inflammation and pain.

Q: Can Proflam (Aceclofenac) be used for a headache or just joint pain?

The official indications listed in core regulatory documents are specific to chronic inflammatory joint conditions, such as arthritis. Use for general conditions such as a headache is not uniformly listed as a primary indication across all major labels.

Q: Are there any food or drinks that interact with Proflam (Aceclofenac)?

Official regulatory documents generally advise taking Aceclofenac with or immediately after food. This administration timing is typically noted on the product label. No specific food or drink interactions are commonly listed in core regulatory documents.

Q: Can Proflam (Aceclofenac) be taken with a mild pain reliever like paracetamol?

Regulatory information indicates that Aceclofenac should not be combined with other nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesic doses of aspirin. The interaction with paracetamol (acetaminophen) is not explicitly listed as a contraindication in core regulatory labels.

Q: Is Proflam (Aceclofenac) considered a strong painkiller?

Aceclofenac is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), which works to reduce inflammation and relieve pain. The term 'strong painkiller' is a descriptive term and is not a formal regulatory classification.

Q: What if I experience unusual bruising while taking Proflam (Aceclofenac)?

Regulatory documents highlight that Aceclofenac may enhance the risk of bleeding. This increased risk is formally noted, especially when combined with medicines like anticoagulants, which necessitates close professional monitoring.

Q: Is there a link between Proflam (Aceclofenac) and sensitivity to sunlight?

Some official regulatory documents list photosensitivity (increased sensitivity to light) as a rare possible adverse reaction for Aceclofenac. It is not listed as a common side effect.

Q: Is Proflam (Aceclofenac) a prescription-only medicine?

In most major jurisdictions, Aceclofenac is generally classified as a Prescription Only Medicine ( Rx-only). This classification means that its dispensing is restricted and requires a medical prescription.

Q: Can Proflam (Aceclofenac) interact with common over-the-counter cold medicines?

Regulatory documents indicate avoiding combining Aceclofenac with other NSAIDs. Since many common over-the-counter cold remedies contain NSAIDs or related components, using them together could increase the risk of adverse effects.

Q: What is the maximum duration of treatment with Proflam (Aceclofenac) mentioned in official guidelines?

Official guidelines do not typically set a single maximum number of days for use. Instead, they mandate using the medicine for the shortest possible duration necessary to manage symptoms, and the ongoing need for therapy is subject to periodic professional re-evaluation.

Q: Are there different strengths or forms of Proflam (Aceclofenac) available?

The most common form documented in regulatory product information is the 100 mg film-coated tablet. Some regions also list other formulations, such as a powder for oral suspension or modified-release products.

Q: Does Proflam (Aceclofenac) interact with herbal supplements?

Specific interactions with individual herbal supplements are often not detailed in core regulatory documents. However, official patient information generally advises disclosing all medications, vitamins, and herbal products to a professional.

Q: Is Proflam (Aceclofenac) used for muscle spasms or only joint stiffness?

The primary official indications focus on the symptomatic relief of pain and inflammation in chronic joint diseases like arthritis. The official label does not typically list muscle spasms as a monotherapy indication.

Q: Can Proflam (Aceclofenac) be taken with medications for diabetes?

Regulatory documents caution that Aceclofenac may affect blood sugar levels when taken alongside antidiabetic drugs. This interaction can, in rare cases, lead to changes such as hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar).

Q: Does the age of the patient change how Proflam (Aceclofenac) affects them?

Official regulatory documents specifically highlight that elderly patients require close monitoring. This is due to their recognized increased vulnerability to certain serious adverse effects, suggesting differences in risk profile related to age.

Q: Is there evidence that Proflam (Aceclofenac) helps with menstrual cramps?

The official indications for Aceclofenac focus on joint diseases (osteoarthritis, rheumatoid arthritis, ankylosing spondylitis). Dysmenorrhea (menstrual cramps) is not listed as a primary or secondary indication in the core regulatory labels.

Q: Can Proflam (Aceclofenac) affect liver function?

Aceclofenac is metabolized in the liver, and use is strictly contraindicated in patients with severe hepatic failure. Caution is required for those with mild-to-moderate liver impairment, as the drug may affect liver enzyme levels.

Q: Is it common for Proflam (Aceclofenac) to cause indigestion?

Yes, indigestion, known medically as dyspepsia, is listed in regulatory documents as a common adverse reaction. This means it has been observed in 1 to 10 out of every 100 users.

Q: Is there a generic version of Proflam (Aceclofenac)?

Proflam is a brand name. The active ingredient is Aceclofenac, which is the International Nonproprietary Name (INN). Generic versions containing the active ingredient Aceclofenac are widely available internationally.

Q: Why does the packaging for Proflam (Aceclofenac) mention not taking it near other specific medications?

The label includes these warnings because combining Aceclofenac with certain other medications can significantly increase the frequency or severity of serious adverse reactions. This includes enhanced risks of bleeding or gastrointestinal damage.

How to Store and Dispose of Proflam (Aceclofenac)

Official regulatory documents define strict conditions for storing and disposing of Aceclofenac to maintain its stability and ensure safety.

Mandatory Storage Requirements

Aceclofenac must be stored at a temperature below 30 C, with some regional requirements specifying storage below 25 C. The product requires mandatory protection from light and should be kept in its original package, typically an aluminium blister. The shelf life is generally three to four years when stored under these conditions.

For safety, the medicine must be kept out of the sight and reach of children and stored in a secure location.

Official Disposal Instructions

Unused or expired Aceclofenac must be disposed of in accordance with local requirements for pharmaceutical waste. Disposal instructions explicitly state that the product must not be released to the environment, drains, or water courses and should be delivered to an approved waste disposal plant.